Need Help?

Immuno-genomic landscape of osteosarcoma

Osteosarcoma is an orphan disease affecting children and young adults that has seen little to no progress in survival outcomes for >30 years. Despite having heavily rearranged genomes, to date, clinical trials with immunotherapy have shown no benefit for patients with osteosarcoma. In this study, we conducted the first multi-platform immune profiling (whole genome, transcriptome, T-cell receptor sequencing, immunohistochemistry and reverse phase protein array) on every available pediatric and adult osteosarcoma patients from our institution (N = 48) with the goal of describing immune features that may contribute to immunotherapy resistance.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001005389 HiSeq X Ten 72
EGAD00001008434 Illumina HiSeq 2000 19
Publications Citations
Molecular features and predictive models identify the most lethal subtype and a therapeutic target for osteosarcoma.
Front Oncol 13: 2023 1111570
2